Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
Clinical trial NCT05270525 · RECRUITING
Trial details
- NCT number
- NCT05270525
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-27
- Primary completion
- 2026-12-01
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.